BridgeBio Pharma Other Long-Term Assets 2018-2024 | BBIO
BridgeBio Pharma other long-term assets from 2018 to 2024. Other long-term assets can be defined as field containing the sum of all non-current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
BridgeBio Pharma Annual Other Long-Term Assets
(Millions of US $) |
| 2023 |
$23 |
| 2022 |
$20 |
| 2021 |
$33 |
| 2020 |
$24 |
| 2019 |
$26 |
| 2018 |
$1 |
| 2017 |
$ |
BridgeBio Pharma Quarterly Other Long-Term Assets
(Millions of US $) |
| 2024-09-30 |
$20 |
| 2024-06-30 |
$19 |
| 2024-03-31 |
$21 |
| 2023-12-31 |
$23 |
| 2023-09-30 |
$19 |
| 2023-06-30 |
$20 |
| 2023-03-31 |
$21 |
| 2022-12-31 |
$20 |
| 2022-09-30 |
$30 |
| 2022-06-30 |
$31 |
| 2022-03-31 |
$35 |
| 2021-12-31 |
$33 |
| 2021-09-30 |
$33 |
| 2021-06-30 |
$50 |
| 2021-03-31 |
$30 |
| 2020-12-31 |
$24 |
| 2020-09-30 |
$16 |
| 2020-06-30 |
$17 |
| 2020-03-31 |
$17 |
| 2019-12-31 |
$26 |
| 2019-09-30 |
$3 |
| 2019-06-30 |
|
| 2019-03-31 |
|
| 2018-12-31 |
|
| 2018-09-30 |
|
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$4.260B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
